Insulin Receptor

Insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of tyrosine kinase receptors. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis, a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

Insulin Receptor Inhibitors, Antagonists, Activators & Modulators

AGL-2263

Cat. No.: HY-112720

AGL-2263 is an **insulin receptor (IR)** blocker.



Purity: 95.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

BMS-536924

Cat. No.: HY-10262

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-754807

Cat. No.: HY-10200

BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor **(IGF-1R)**/insulin receptor family kinases **(IR)** with IC_{50} of 1.8 and 1.7 nM, respectively and K_i of <2 nM for both, and also shows potent activities against Met, RON, TrkA, TrkB, AurA,...



Purity: 99.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceritinib

(LDK378)

Cat. No.: HY-15656

Ceritinib (LDK378) is a potent and specific **ALK** inhibitor with an IC_{50} of 0.2 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib dihydrochloride

(LDK378 (dihydrochloride))

Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC_{50} of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Insulin levels modulator

Cat. No.: HY-112819

Insulin levels modulator could be used to treat diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Insulin(cattle)

(Insulin from bovine pancreas)

Cat. No.: HY-P1156

Insulin cattle is a kind of polypeptide hormone that regulates glucose metabolism in pancreatic islet B-cells.

Insulin(cattle)

Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Insulin(human)

Cat. No.: HY-P0035

Insulin(human) is a polypeptide hormone that regulates the level of glucose.

Insulin (human)

Purity: 96.90%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Kaempferitrin

(Lespedin; Lespenephryl)

Cat. No.: HY-N0628

Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates **insulin** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

KU14R

Cat. No.: HY-15481

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Linsitinib

(OSI-906)

Cat. No.: HY-10191

Linsitinib (OSI-906) is a dual inhibitor of the **IGF-1 receptor** and **insulin receptor** with IC_{50}s of 35 and 75 nM, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MSDC 0160

(Mitoglitazone; CAY10415)

Cat. No.: HY-100550

MSDC 0160 act as an insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC), a key controller of cellular metabolism that influences mTOR (mammalian target of rapamycin) activation. In Vitro: MSDC-0160 acts as insulin sensitizers without activating PPARγ.



Purity: >98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-AEW541

(AEW541)

Cat. No.: HY-50866

NVP-AEW541 is a potent inhibitor of **IGF-1R** with IC_{50} of 0.15 μM, also inhibits **InsR**, with IC_{50} of 0.14 μM.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rhoifolin

Cat. No.: HY-N0755

Rhoifolin is a flavone glycoside isolated from Citrus grandis (L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation of **insulin receptor-β** and glucose transporter 4 (GLUT 4) translocation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg